CY-219

N/A

Report date: 2026/05/02 20:00:18

Base Information

Drug NameCY-219

Drug Alias NameCY-219

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacements

TargetsUpdating

Therapy Area/IndicationsLarge B Cell LymphomaLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesInstitute Of Hematology & Blood Diseases Hospital

China Registration ClassN/A

Develop Information

Active CompaniesInstitute Of Hematology & Blood Diseases Hospital

Inactive CompaniesN/A

Active IndicationsLarge B Cell LymphomaLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A